Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

China geopolitical tensions, China's Fosun Pharmaceutical is in discussions with three global private equity firms to sell ...

India's future is being shaped by a new wave of innovative companies revolutionizing industries through technology, ...

Foreign participants at the 16th Asia Pharma Expo foresee a bright future for Bangladesh’s pharmaceutical industry, given its ...

As the Dec quarter earnings season nears its end, HAL, Ashok Leyland, Natco Pharma and Jubilant Foodworks are few of the key ...

With a 10% tariff making Chinese products costlier, US importers may turn to Indian companies as cost-effective alternatives.

The implementation of the revised Schedule M marks a critical step towards enhancing the quality and safety of pharmaceutical ...

The Union Health Ministry has conditionally extended the deadline for implementing the revised Schedule M, a set of good manufacturing practices for small and medium pharmaceutical companies, till ...

Thales and India’s BDL are set to supply first batch of LBRM Very Short Range Air Defence (VSHORAD) Missiles and launchers to ...

India's Ministry of Health & Family Welfare extends the Schedule M implementation deadline for small & medium pharma firms with turnover under Rs 250 crore till December 31, 2025.

Find all the latest Q3 results 2025 updates for TVS Srichakra, Rail Vikas Nigam, Shriram Properties, Ashok Leyland, Saint ...

The finest minds from the pharma firmament will also be sharing insights on the changing landscape and on the new imperatives ...